Aug. 19 at 2:09 PM
$GANX Another deal for an asset just starting safety testing Phase 1/2 in healthy volunteers in rare genetic bone disorder that already has a therapy.
BioMarin bulks up bone unit with
$275M Alesta buyout to challenge AstraZeneca
BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for
$275 million upfront, positioning the biopharma to challenge AstraZeneca for a rare bone disease market.
Alesta is developing a small molecule to treat hypophosphatasia (HPP), a rare genetic bone disease. The pediatric HPP market is already served by AstraZeneca’s enzyme replacement therapy (ERT) Strensiq, and the Big Pharma has tipped its next-generation asset to generate blockbuster sales. Yet the limitations of Strensiq and ERT more broadly leave a potential opportunity open to competitors.
